Peter Diamandis - Jun 20, 2023 Form 4 Insider Report for Vaxxinity, Inc. (VAXX)

Role
Director
Signature
/s/ Rene Paula Molina, attorney-in-fact for Peter Diamandis
Stock symbol
VAXX
Transactions as of
Jun 20, 2023
Transactions value $
$0
Form type
4
Date filed
6/26/2023, 06:32 PM
Previous filing
Jun 16, 2023

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VAXX Stock option (right to buy) Award $0 +132K $0.00 132K Jun 20, 2023 Class A common stock 132K $2.21 Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These options were automatically granted following the Issuer's annual shareholders meeting pursuant to a policy adopted by the Issuer's board of directors providing for annual non-employee director compensation.
F2 These options vest on the earliest of (i) the one-year anniversary of the grant date, (ii) the following year's annual stockholder meeting, and (iii) a Change in Control (as defined in the Vaxxinity, Inc. 2021 Omnibus Incentive Compensation Plan), in each case, subject to the Reporting Person's continued service with the Issuer through the vesting date.
F3 These stock options shall expire upon the earlier of (i) the tenth anniversary of the grant date, and (ii) three months after the date the Reporting Person ceases to be a director, officer, employee or consultant of the Issuer or one of its affiliates.